• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

截至2021年11月21日的数据显示，欧洲国家未接触过新冠病毒的人群以及潜在的新冠住院和死亡情况。

Unexposed populations and potential COVID-19 hospitalisations and deaths in European countries as per data up to 21 November 2021.

作者信息

Chapman Lloyd A C, Barnard Rosanna C, Russell Timothy W, Abbott Sam, van Zandvoort Kevin, Davies Nicholas G, Kucharski Adam J

机构信息

Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.

出版信息

Euro Surveill. 2022 Jan;27(1). doi: 10.2807/1560-7917.ES.2022.27.1.2101038.

DOI:10.2807/1560-7917.ES.2022.27.1.2101038
PMID:34991776
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8739340/
Abstract

We estimate the potential remaining COVID-19 hospitalisation and death burdens in 19 European countries by estimating the proportion of each country's population that has acquired immunity to severe disease through infection or vaccination. Our results suggest many European countries could still face high burdens of hospitalisations and deaths, particularly those with lower vaccination coverage, less historical transmission and/or older populations. Continued non-pharmaceutical interventions and efforts to achieve high vaccination coverage are required in these countries to limit severe COVID-19 outcomes.

摘要

我们通过估算19个欧洲国家中已通过感染或接种疫苗获得重症免疫的人口比例，来估计这些国家中潜在的剩余新冠住院和死亡负担。我们的结果表明，许多欧洲国家仍可能面临较高的住院和死亡负担，尤其是那些疫苗接种覆盖率较低、既往传播率较低和/或人口老龄化的国家。这些国家需要继续采取非药物干预措施并努力实现高疫苗接种覆盖率，以限制新冠重症后果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e1f/8739340/6d168df29afa/2101038-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e1f/8739340/07d01c736c8f/2101038-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e1f/8739340/faced04b2593/2101038-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e1f/8739340/a54d50e461c0/2101038-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e1f/8739340/6d168df29afa/2101038-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e1f/8739340/07d01c736c8f/2101038-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e1f/8739340/faced04b2593/2101038-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e1f/8739340/a54d50e461c0/2101038-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e1f/8739340/6d168df29afa/2101038-f4.jpg

相似文献

1
Unexposed populations and potential COVID-19 hospitalisations and deaths in European countries as per data up to 21 November 2021.截至2021年11月21日的数据显示，欧洲国家未接触过新冠病毒的人群以及潜在的新冠住院和死亡情况。
Euro Surveill. 2022 Jan;27(1). doi: 10.2807/1560-7917.ES.2022.27.1.2101038.
2
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.在以色列全国范围内使用辉瑞-生物科技公司的 BNT162b2 mRNA COVID-19 疫苗进行疫苗接种运动，以预防感染、住院和死亡：一项回顾性监测研究。
Lancet Infect Dis. 2022 Mar;22(3):357-366. doi: 10.1016/S1473-3099(21)00566-1. Epub 2021 Sep 22.
3
Hospitalisations and Deaths Averted by COVID-19 Vaccination in Navarre, Spain, 2021-2022.2021 - 2022年西班牙纳瓦拉地区新冠疫苗接种避免的住院和死亡情况
Vaccines (Basel). 2024 Jan 7;12(1):58. doi: 10.3390/vaccines12010058.
4
Assessing real-world vaccine effectiveness against severe forms of SARS-CoV-2 infection: an observational study from routine surveillance data in Switzerland.评估 SARS-CoV-2 感染严重形式的真实世界疫苗有效性：来自瑞士常规监测数据的观察性研究。
Swiss Med Wkly. 2022 Apr 19;152:w30163. doi: 10.4414/smw.2022.w30163. eCollection 2022 Apr 11.
5
Initial assessment of the COVID-19 vaccination's impact on case numbers, hospitalisations and deaths in people aged 80 years and older, 15 EU/EEA countries, December 2020 to May 2021.2020 年 12 月至 2021 年 5 月，15 个欧盟/欧洲经济区国家 80 岁及以上人群中 COVID-19 疫苗接种对病例数量、住院和死亡的初步评估。
Euro Surveill. 2021 Dec;26(48). doi: 10.2807/1560-7917.ES.2021.26.48.2101030.
6
COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study.苏格兰 257 万人中 BNT162b2 和 ChAdOx1 nCoV-19 疫苗接种后 COVID-19 住院和死亡情况（EAVE II）：一项前瞻性队列研究。
Lancet Respir Med. 2021 Dec;9(12):1439-1449. doi: 10.1016/S2213-2600(21)00380-5. Epub 2021 Sep 29.
7
COVID-19 vaccinations and rates of infections, hospitalizations, ICU admissions, and deaths in Europe during SARS-CoV-2 Omicron wave in the first quarter of 2022.2022 年第一季度，在欧洲 SARS-CoV-2 奥密克戎波期间，COVID-19 疫苗接种率与感染、住院、重症监护病房入院和死亡。
J Med Virol. 2023 Jan;95(1):e28131. doi: 10.1002/jmv.28131. Epub 2022 Sep 14.
8
Demographics of COVID-19 hospitalisations and related fatality risk patterns.COVID-19 住院患者的人口统计学特征及相关病死率模式。
Health Policy. 2022 Oct;126(10):945-955. doi: 10.1016/j.healthpol.2022.07.005. Epub 2022 Jul 23.
9
Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.确定流感疫苗接种在欧盟25个国家内对健康和经济的影响。
Vaccine. 2006 Nov 17;24(47-48):6812-22. doi: 10.1016/j.vaccine.2006.07.042. Epub 2006 Aug 4.
10
Estimating averted COVID-19 cases, hospitalisations, intensive care unit admissions and deaths by COVID-19 vaccination, Italy, January-September 2021.估算意大利 2021 年 1 月至 9 月因 COVID-19 疫苗接种而避免的 COVID-19 病例、住院、重症监护病房入院和死亡人数。
Euro Surveill. 2021 Nov;26(47). doi: 10.2807/1560-7917.ES.2021.26.47.2101001.

引用本文的文献

1
Science-based exit from stringent countermeasures against COVID-19: Mortality prediction using immune landscape between 2021 and 2022 in Japan.基于科学的新冠疫情严格防控措施解除：利用日本2021年至2022年免疫格局进行死亡率预测
Vaccine X. 2024 Aug 12;20:100547. doi: 10.1016/j.jvacx.2024.100547. eCollection 2024 Oct.
2
Predicting subnational incidence of COVID-19 cases and deaths in EU countries.预测欧盟国家 COVID-19 病例和死亡的国家级别发病率。
BMC Infect Dis. 2024 Feb 14;24(1):204. doi: 10.1186/s12879-024-08986-x.
3
Predictive models for health outcomes due to SARS-CoV-2, including the effect of vaccination: a systematic review.

本文引用的文献

1
Statistical Deconvolution for Inference of Infection Time Series.统计去卷积推断感染时间序列。
Epidemiology. 2022 Jul 1;33(4):470-479. doi: 10.1097/EDE.0000000000001495. Epub 2022 May 10.
2
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.德尔塔变异株对英国新冠病毒载量及针对新型严重急性呼吸综合征冠状病毒2感染的疫苗效力的影响。
Nat Med. 2021 Dec;27(12):2127-2135. doi: 10.1038/s41591-021-01548-7. Epub 2021 Oct 14.
3
Considerations in boosting COVID-19 vaccine immune responses.
预测 SARS-CoV-2 导致的健康结果的模型，包括疫苗接种的效果：系统评价。
Syst Rev. 2024 Jan 16;13(1):30. doi: 10.1186/s13643-023-02411-1.
4
Genomic surveillance reveals dynamic shifts in the connectivity of COVID-19 epidemics.基因组监测揭示了新冠疫情传播链的动态变化。
Cell. 2023 Dec 21;186(26):5690-5704.e20. doi: 10.1016/j.cell.2023.11.024. Epub 2023 Dec 14.
5
Real-time surveillance of international SARS-CoV-2 prevalence using systematic traveller arrival screening: An observational study.利用系统的旅行者抵达筛查实时监测国际 SARS-CoV-2 流行情况：一项观察性研究。
PLoS Med. 2023 Sep 8;20(9):e1004283. doi: 10.1371/journal.pmed.1004283. eCollection 2023 Sep.
6
Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study.SARS-CoV-2 血清学检测敏感性的动态变化：系统评价和模型研究。
Euro Surveill. 2023 May;28(21). doi: 10.2807/1560-7917.ES.2023.28.21.2200809.
7
The Impact of COVID-19 Vaccination on the Social Participation of Immunocompromised Persons - Results of a Multicenter Observational Study.新冠疫苗接种对免疫功能低下人群社会参与的影响 - 一项多中心观察性研究的结果。
Front Public Health. 2022 Jun 10;10:877623. doi: 10.3389/fpubh.2022.877623. eCollection 2022.
8
Is Mandatory Vaccination in Population over 60 Adequate to Control the COVID-19 Pandemic in E.U.?欧盟60岁以上人群强制接种疫苗足以控制新冠疫情吗？
Vaccines (Basel). 2022 Feb 18;10(2):329. doi: 10.3390/vaccines10020329.
增强新冠病毒疫苗免疫反应的考量因素。
Lancet. 2021 Oct 9;398(10308):1377-1380. doi: 10.1016/S0140-6736(21)02046-8. Epub 2021 Sep 14.
4
COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.COVID-19 疫苗：紧跟 SARS-CoV-2 变异株。
Cell. 2021 Sep 30;184(20):5077-5081. doi: 10.1016/j.cell.2021.09.010. Epub 2021 Sep 17.
5
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.使用BNT162b2疫苗第三剂对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）进行中和
N Engl J Med. 2021 Oct 21;385(17):1627-1629. doi: 10.1056/NEJMc2113468. Epub 2021 Sep 15.
6
Practical considerations for measuring the effective reproductive number, Rt.测量有效繁殖数，Rt 的实用考虑因素。
PLoS Comput Biol. 2020 Dec 10;16(12):e1008409. doi: 10.1371/journal.pcbi.1008409. eCollection 2020 Dec.
7
Age-specific mortality and immunity patterns of SARS-CoV-2.SARS-CoV-2 的年龄特异性死亡率和免疫模式。
Nature. 2021 Feb;590(7844):140-145. doi: 10.1038/s41586-020-2918-0. Epub 2020 Nov 2.
8
Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.估算非药物干预措施对欧洲 COVID-19 疫情的影响。
Nature. 2020 Aug;584(7820):257-261. doi: 10.1038/s41586-020-2405-7. Epub 2020 Jun 8.
9
Estimating the burden of SARS-CoV-2 in France.估算法国 SARS-CoV-2 的负担。
Science. 2020 Jul 10;369(6500):208-211. doi: 10.1126/science.abc3517. Epub 2020 May 13.